Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-126 extension study in schizophrenia
NCT01834638Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Mar 2013
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of nelonicline in schizophrenia, sponsored by AbbVie Inc.. Started Mar 2013; status: terminated.
02
Drugs
nelonicline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01834638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834638.